Updates in Hereditary Angioedema Care from HAEA
March 30, 2023
November 29, 2024
Scroll to the Bottom of this Information to Begin this Course
Jointly provided by RMEI Medical Education, LLC and the US Hereditary Angioedema Association (HAEA).
Funding provided by the US Hereditary Angioedema Association (HAEA). No commercial support provided for this accredited continuing education activity.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hour(s)
- Pharmacists — 1.0 Contact Hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of clinicians involved in the diagnosis and management of patients with hereditary angioedema (HAE).
This activity will cover HAE genetics and diagnostics with a focus on HAE-nl-C1INH, emerging therapies, and patient-centered care.
Learning ObjectivesUpon completion of this activity, participants should be better able to:
- Integrate new developments in hereditary angioedema (HAE) genetic and diagnostic testing
- Utilize clinical guidelines to select treatment for prophylaxis and acute attacks in patients with HAE
- Provide patient-centered care using individualized management plans and educational resources
Anthony J. Castaldo
Fairfax City, VA
Bruce L. Zuraw, MD
Professor, Medicine, UCSD Department of Medicine
Director, US HAE Angioedema Center at UCSD University of California School of Medicine
La Jolla, CA
Research Scientist, Veterans Medical Research Foundation
VA Staff Physician and Chief, Section of Allergy San Diego
Veterans Affairs Medical Center
San Diego, CA
Bruce L. Zuraw, MD, is a professor of medicine and director of the US HAE Angioedema Center at the University of California San Diego School of Medicine in La Jolla, CA. He is also a research scientist and VA staff physician and chief at the San Diego Veterans Affairs Medical Center. Dr Zuraw received his medical degree from Loyola University Chicago Stritch School of Medicine in Maywood, IL, where he also completed his residency in internal medicine. Dr Zuraw then served as a postdoctoral fellow and chief clinical fellow at the Scripps Clinic & Research Foundation in La Jolla, CA. He is board certified in internal medicine and allergy and immunology.
Dr Zuraw’s research focuses on allergic inflammation in humans, with particular attention to hereditary angioedema. He has published more than 300 papers, book chapters, abstracts, and other publications in the field of allergy and immunology, and has served as a journal reviewer for 24 journals and multiple grant review committees. He has also served as an invited editor for Immunology and Allergy Clinics of North America (angioedema volume).
Dr Zuraw has received numerous honors and awards for his contributions to the field, including being on the Best Doctors in America® list and receiving the AAAAI Distinguished Clinician Award for his work in hereditary angioedema.
Aleena Banerji, MD
Associate Professor, Medicine
Harvard Medical School
Program and Assistant Clinical Director
Allergy and Immunology Training Program Division of Rheumatology, Allergy and Immunology
Massachusetts General Hospital
Aleena Banerji, MD, is an associate professor of medicine at Harvard Medical School and the program and assistant clinical director of the Allergy and Immunology Fellowship Training Program in the Division of Rheumatology, Allergy and Immunology at Massachusetts General Hospital in Boston, MA. She completed her medical school training at Northwestern University in Evanston, IL and then her fellowship training in allergy and immunology at Massachusetts General Hospital. Dr Banerji is board certified in allergy and immunology.
Dr Banerji’s research interests are in the field of drug allergy and angioedema. As a result of her work, she has many first author publications and has gained a strong national reputation. She has not only actively participated as an investigator on multiple large clinical trials in hereditary angioedema but has also helped create guidelines to improve the management of patients with drug allergy and angioedema. Dr Banerji remains very active in trying to better understand the burden of disease in these patients to improve management strategies.
William R. Lumry, MD
Clinical Professor, Internal Medicine
University of Texas Southwestern Medical School
William R. Lumry, MD, is in private practice in Dallas, TX. He treat adults and children with allergic diseases, asthma, and immunodeficiency. He is also a clinical professor of internal medicine at the University of Texas Southwestern Medical School and teaches at Parkland Memorial Hospital in Dallas, TX. Dr Lumry received his medical degree from the University of Texas Medical Branch at Galveston, and completed his internal medicine training at Barnes-Jewish Hospital at Washington University in St. Louis, MO and his clinical and research fellowship in allergy and immunology at Scripps Clinic and Research Institute in La Jolla, CA. Dr Lumry is board certified in allergy and immunology and internal medicine.
Dr Lumry is a fellow of the American Academy of Allergy, Asthma and Imunology, the American College of Allergy, Asthma and Immunology, and the American College of Physicians. He is a past-President of the Texas Allergy, Asthma and Immunology Society, past-President of the American Lung Association – Dallas Area, and a Founding Director of the Asthma and Allergy Foundation of America – Texas Chapter.
Dr Lumry has been honored with the Outstanding Teaching Award from the University of Texas Southwestern Allergy and Immunology Division and with the Outstanding Volunteer Clinical Faculty Award from the American Academy of Allergy, Asthma and Immunology. He is also the Medical Director of the AARA Research Center, which participates actively in clinical research projects involving new treatments for asthma, allergic and immune deficiency diseases, and hereditary angioedema.
Marc A. Riedl, MD, MS
Clinical Director, US HAEA Angioedema Center
Clinical Service Chief, Allergy & Immunology
Division of Rheumatology, Allergy & Immunology
University of California, San Diego
San Diego, CA
Marc A. Riedl, MD, MS, is a professor of medicine at the University of California, San Diego (UCSD), and the clinical director of the US HAEA Angioedema Center at UCSD in La Jolla, CA, where he also serves as the clinical service chief for allergy-immunology. Dr Riedl received his medical degree from the University of Chicago–Pritzker School of Medicine in Chicago, IL. He then completed his residency in internal medicine at Barnes-Jewish Hospital of Washington University in St. Louis, MO and a fellowship in clinical immunology and allergy at the University of California, Los Angeles. Dr Riedl received a Master of Science degree in clinical research and completed advanced training in clinical pharmacology at UCLA. Dr Riedl is board certified in allergy and immunology and clinical pharmacology.
Dr Riedl’s professional interests include angioedema conditions and primary immunodeficiencies. He has published extensively in these areas, serves on numerous editorial boards and scientific committees, as well as appointed expert panels for the FDA and NIH, and directs an active clinical research program at UCSD.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and the US Hereditary Angioedema Association (HAEA). RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008290-9999-23-003-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Anthony J. Castaldo, has no relevant financial relationship(s) with ineligible companies to disclose.
- Aleena Banerji, MD
- Consultant: BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharvaris, Takeda
- Researcher: BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., KalVista Pharma, Takeda
- William R. Lumry, MD
- Consultant: Astria, BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia Therapeutics, Inc., KalVista Pharma, Magellan, Optum, Pharming Group N.V., Pharvaris, Shire, Takeda
- Grant/Research Support: CSL Behring, Grifols S.A., Ionis Pharmaceuticals, Inc., KalVista Pharma, Shire/Takeda, Teva Pharmaceuticals USA
- Speakers’ Bureau: AstraZeneca, BioCryst Pharmaceuticals, CSL Behring, Grifols S.A., GSK, OptiNose, Inc, Pharming Group N.V., Shire/Takeda, Sanofi/Regeneron
- Marc A. Riedl, MD, MS
- Consultant: Astria, BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Cycle Pharmaceuticals Ltd, Grifols S.A., Intellia Therapeutics, Inc., Ipsen, KalVista Pharma, Ono Pharmaceutical Co., Ltd, Pfizer, Pharming Group N.V., Pharvaris, REGENXBIO Inc., Sanofi/Regeneron, Spark, Takeda
- Grant/Research Support: BioCryst Pharmaceuticals, BioMarin Pharmaceuticals Inc., CSL Behring, Ionis Pharmaceuticals, Inc., KalVista Pharma, Pharvaris, Takeda
- Speaker/Speakers’ Bureau: Grifols S.A., Pharming Group N.V., Takeda
- Bruce L. Zuraw, MD
- Consultant: BioCryst Pharmaceuticals, CSL Behring, Takeda
- Independent Contractor, including Contracted Research: Ionis Pharmaceuticals, Inc.
- Other, Data Safety Monitoring: BioMarin Pharmaceuticals Inc., Genentech, Novartis
All of the relevant financial relationships for these individuals have been mitigated according to RMEI policies.
Planners and Managers
All planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Method of Participation and Request for Credit
In order to receive credit, participants must review the activity content and complete the evaluation. A statement of credit will be available to print immediately. If you have questions about this activity, please contact RMEI at [email protected].
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation
There is no fee to participate.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.